Myeloperoxidase: a new target for the treatment of stroke?

Abstract
Myeloperoxidase is an important inflammatory factor in the myeloid system, primarily expressed in neutrophils and microglia. Myeloperoxidase and its active products participate in the occurrence and development of hemorrhagic and ischemic stroke, including damage to the blood-brain barrier and brain. As a specific inflammatory marker, myeloperoxidase can be used in the evaluation of vascular disease occurrence and development in stroke, and a large amount of experimental and clinical data has indicated that the inhibition or lack of myeloperoxidase has positive impacts on stroke prognosis. Many studies have also shown that there is a correlation between the overexpression of myeloperoxidase and the risk of stroke. The occurrence of stroke not only refers to the first occurrence but also includes recurrence. Therefore, myeloperoxidase is significant for the clinical evaluation and prognosis of stroke. This paper reviews the potential role played by myeloperoxidase in the development of vascular injury and secondary brain injury after stroke and explores the effects of inhibiting myeloperoxidase on stroke prognosis. This paper also analyzes the significance of myeloperoxidase etiology in the occurrence and development of stroke and discusses whether myeloperoxidase can be used as a target for the treatment and prediction of stroke.

Key Words: blood-brain barrier; hemorrhagic stroke; inflammation; ischemic stroke; microglia; myeloperoxidase; neutrophils; secondary brain injury; stroke

Introduction
Stoke refers to a series of cerebrovascular diseases that cause brain damage due to changes in blood flow and oxygen delivery mediated by blood vessels. Depending on whether the cause of stroke is central nervous system hemorrhage or thrombotic ischemia, stroke can be classified as ischemic stroke and hemorrhagic stroke (Bedard and Krause, 2007; Liang et al., 2020), and ischemic stroke is the most common type, accounting for approximately 70% of all strokes. According to the 2017 Global Burden of Disease study (GBD), stroke is responsible for more than 5% of all disability-adjusted life years, and stroke was responsible for 11% of all deaths worldwide, which is equivalent to 6.17 million deaths due to stroke each year, ranking third among all causes of death (GBD 2016 DALYs and HALE Collaborators, 2017; GBD 2017 Causes of Death Collaborators, 2018; Avan et al., 2019; Deuschl et al., 2020). The GBD 2016 Lifetime Risk of Stroke Collaborators (2018), involving GBDs in various regions of the world, was published by the New England Journal of Medicine. The results showed over the past 26 years, the global risk of lifelong stroke among adults increased by 8.9% to 24.9% (95% confidence interval [CI] 23.5–26.2%), with a male risk of 24.7% (95% CI 23.3–26.2%) and a female risk of 25.1% (95% CI 23.7–26.5%), indicating that almost one-quarter of all adults are at risk of experience stroke during their lifetimes. Among all adults included in relevant studies, 18.3% are likely to experience an ischemic stroke, and 8.2% are likely to experience a hemorrhagic stroke. During the period from 1990 to 2016, the stroke incidence in China increased from 204.52 to 403.08 per 100,000 population, and mortality increased from 122.09 to 130.94 per 100,000 population (Wang et al., 2020). High blood pressure, heart disease, diabetes, atherosclerosis, lack of exercise, high blood fat, high-salt diet, smoking, alcoholism, and age have been identified as risk factors for stroke (George, 2020; Mai and Liang, 2020; Zhang et al., 2020). After stroke, the inflammatory system is activated. During the early stages of hemorrhagic stroke, the brain tissue surrounding the hematoma is characterized by the infiltration of inflammatory cells and inflammatory factors, such as free radicals and proteases, produced by neurons. These early inflammatory factors, including myeloperoxidase (MPO), continue to damage the brain during the whole process of the hematoma incident (Wang, 2010).

MPO is an important inflammatory factor in the myeloid system (Klebanoff, 2005). Agner (1941) first isolated and purified the heme peroxidase-containing MPO from the green purulent fluid obtained from tuberculosis patients; due to its green appearance, MPO is also known as verdoperoxidase (Klebanoff, 2005; Ray and Katyal, 2016). MPO is abundantly expressed in neutrophils and other myeloid cells, such as Ly-6Chigh monocytes (Swirski et al., 2009; Grishkovskaya et al., 2017), macrophages, and microglia (Gray et al., 2008; Geihaar et al., 2017). After acute cerebral ischemia, due to the destruction of the blood–brain barrier (BBB), the infiltration of a large number of neutrophils attacks the central nervous system. Studies have shown...
that the large growth in the neutrophil population is accompanied by a large increase in MPO production (Gorudko et al., 2017; Reber et al., 2017; Pleskova et al., 2018; Maestrini et al., 2020). Large amounts of inflammation are observed during the early stages of stroke, and the activation of phagosomes represents an important form of inflammation. MPO is an important enzyme in phagocyte vacuoles. Among the antimicrobial systems present in the phagosome, a significant proportion consists of MPO, hydrogen peroxide (H₂O₂, formed during the respiratory burst), and a halide (X⁻), particularly chloride (Cl⁻) (Iana and Sirbu, 2020; Marcinkiewicz and Walczewska, 2020). In the MPO-H₂O₂-CF sterilization system, the oxidant chlorous acid is selected from the latest articles published in authoritative journals. Exclusion criteria were repetitive or retrospective studies. Two researchers (YCW and YBL) independently read and screened the articles by reading the titles and abstracts and then combined the screening results. After the readers reported controversial documents, YNZ and YWP discussed whether to include them. Any articles unrelated to stroke and myeloperoxidase and among highly similar studies, only the most recently published article was retained. In the end, 106 articles were included in the reference catalog.

The Role of MPO in Vascular Injury before Stroke

Stroke is classified as a vascular disease. When blood vessels are damaged due to malformations in arteriovenous blood vessels, a thrombus can form, leading to ischemic stroke, whereas hemorrhagic stroke results from the rupture of cerebral vessels. As a cornerstone of the pathophysiological mechanisms of these vascular diseases, MPO damages the arterial wall through either direct oxidation reactions with components of the arterial wall or indirect damage exerted on the integrity and function of the blood vessel (Figure 1). Indeed, the mechanism of how MPO damages brain tissue is (i) the promotion of extracellular matrix degradation and formation of foamy macrophages, resulting in the formation of a core rich in low-density lipoproteins; (ii) changes in serum cholesterol function, distribution, and flow due to lipid peroxidation; (iii) promoting the rupture and instability of atherosclerotic plaques due to oxidation of low-density lipoprotein (LDL) (MMPs and MMP-9) are the enzymes responsible for the degradation of local occlusive thrombus through P-selectin interactions; and (v) the impairment of vascular reactivity through the depletion of endothelial-derived nitric oxide (NO), damaging vasodilatation and anti-inflammatory properties (Vita et al., 2004; Lau and Baldus, 2006; Nicholls and Hazen, 2009).

Molecular damage mechanisms mediated by MPO after stroke

The BBB is a highly specialized system for restricting interactions between the brain parenchyma and the bloodstream, maintaining the function of brain homeostasis. After a stroke, damage to the BBB is an important contributor to cerebral edema and hemorrhagic transformation (Lin et al., 2017). BBB damage can promote lacunar infarction, white matter lesions, and microhemorrhages in deep brain structures and trigger the production of a large number of neurotoxic substances, which directly induce endothelial cell damage to increase vascular permeability (Villanueva et al., 2011). The infiltration of neutrophils can upregulate peptidyl arginine deiminase 4, stimulate interferon genes, and interferon regulatory factor 3. Peptidyl arginine deiminase 4 is a key enzyme involved in chromatin decondensation (Wang et al., 2009; Martind et al., 2013). Stimulator of interferon genes is a DNA sensor, and the upregulation of interferon regulatory factor 3 can induce the production of interferon-β in large quantities, which can disrupt vascular reconstruction and vascular repair after stroke (Kang et al., 2020).

Microglia are another innate immune cell type in the nervous system associated with MPO, which plays a crucial role after stroke occurrence (Qin et al., 2019; Xu et al., 2021). After a stroke occurs, the function of microglia primarily depends on the activation signal received (Ma et al., 2017; Al Mamun et al., 2018). M1 type microglia represent a pro-inflammatory cell type, which primarily contributes to the early stages of stroke and can produce pro-inflammatory mediators (Feng et al., 2017), interleukin (IL)-1β (Facca et al., 2018), interferon-γ (Hwang and Bergmann, 2020), inducible NO synthase (Maksoud et al., 2021), and proteolytic enzymes (MMP9 and MMP3) (Bonetti et al., 2019). The secretion of M1 type microglia exerts anti-inflammatory effects (Jiang et al., 2018), producing IL-10 (Lobo-Silva et al., 2017), transforming growth factor β (Spitau et al., 2020), and vasodilatory growth factor (Li et al., 2020), and vascular endothelial growth factor (Ju et al., 2019), which are pro-angiogenic and anti-inflammatory (Ponomarev et al., 2013). Therefore, MPO-related damage is primarily mediated by M1 microglia (Figure 2).

MPO can form HOCl/OCl⁻ in the presence of chloride ions and H₂O₂. These products are important substances that allow the body to resist microbial attacks (Babior, 1984; Nybo et al., 2019). However, excessive HOCl produced by the MPO-H₂O₂-CF system in neutrophils and monocytes can damage various biological tissues, including the BBB (Klebanoff, 2005). Low-dose HOCl can trigger cell apoptosis, whereas high-dose HOCl can induce cell necrosis, including in neuronal cells and astrocytes, which are the main components of the BBB (Pullar et al., 2000; Whiteman et al., 2005). As a weak acid (acid dissociation constant of 7.5) (Morris, 1966; Wei et al., 1999), HOCl-induced cellular acidosis is unlikely to be the cause of HOCl neurotoxicity. Recent studies have shown that the production of HOCl can activate an increase in the concentration of calpain. The activation of platelets can induce changes in platelet morphology. Similar to caspase-mediated cell apoptosis (Wolf et al., 1999), the activation of calpain can induce cell lysosomes releasing HOCl and resulting in the robust occurrence of secondary damage in the central nervous system after stroke. BMVECs forms the morphological basis of the BBB through the formation of tight junction complexes (Swastika et al., 2019). Bernhart et al. (2018) showed that peripheral blood leukocytes produce HOCl through the MPO-H₂O₂-CF system, which in turn produces chlorinated inflammatory mediators, such as 2-chlorohexadecanoic acid. 2-Chlorohexadecanoic acid can produce a lipid-toxic reaction in BMVECs, destroying the basic BBB structure, further aggravating secondary damage following stroke. Secondary injuries after stroke include hematoma expansion, perihematomal edema, and neurological deterioration (Castellazo et al., 2010).

In addition to the direct and indirect destruction of the BBB by HOCl, MPPs are crucial for BBB destruction. MPPs are proteolytic, zinc-containing enzymes responsible for the degradation of the extracellular matrix by converting the blood-brain barrier in the central nervous system (Zhang and Kim, 2009; Fazal and Al-Ghoul, 2017; Yeo et al., 2020). The activation of MPPs can also induce tight junction degradation, leading to BBB breakdown following cerebral ischemia-reperfusion injury (Ancitl et al., 2005; Nakamato et al., 2020). Fu et al. (2001) showed that HOCl oxidizes the core rich in low-density lipoproteins, which results in per-endothelial microvascular endothelial cell lysis. Recent Studies showed that HOCl significantly enhanced the proteolytic activity of MMP8 and MMP9 (Weiss et al., 1985; Peppin and Weiss, 1986). Furthermore, the 4-amino benzoic acid amide-
Myeloperoxidase (MPO)-related cascade after stroke.

MPO may promote stroke due to damage to the arterial wall through direct oxidation and indirect effects on blood vessel integrity and function, driving a core rich in low-density lipoprotein and promoting the formation of atherosclerotic plaques by foamy macrophages. These plaques affect the function, distribution, and flow of serum cholesterol due to lipid peroxidation. The activation of matrix metalloproteinases leads to atherosclerotic plaque rupture and instability, which can stimulate local occlusive thrombosis through P-selectin interactions. Depleting nitric oxide (NO) can impair vasodilation resistance against inflammation and impair vascular reactivity.

ROS: reactive oxygen species; ONOO\(^{-}\): peroxynitrite; HOCl: hypochlorous acid; iNOS: inducible nitric oxide synthase; NADPH: nicotinamide adenine dinucleotide phosphate; NADPH oxidase: very important pro-oxidase that causes oxidative stress; MnSOD: manganese superoxide dismutase; NOS: nitric oxide synthase; NO: nitric oxide; ONOO\(^{-}\): peroxynitrite; O\(_2\): superoxide anion; HOCl: hypochlorous acid; NO\(_2\): nitrate; NO\(_3\): nitrite; BCECF: bis (2- carboxyethyl) fluorescein; MPO: myeloperoxidase; H\(_2\)-ClHA: 2-Chlorohexadecanoic acid; BBB: blood-brain barrier; Cl\(^{-}\): chloride; Cl\(^{-}\)\(^{\bullet}\): chloride ion; iNOS: inducible nitric oxide synthase; ROS: reactive oxygen species; NOS: nitric oxide synthase; O\(_2\)-: superoxide anion; ONOO\(^{-}\): peroxynitrite; HOCl itself can also exacerbate oxidative stress, promote the translucence of p67(phox) and p47(phox), activating nicotinamide adenine dinucleotide phosphate (NADPH) oxidase and mediating the production of ROS in vascular endothelial cells; NO\(_2\): nitrate; NO\(_3\): nitrite; NO\(_2\)-: nitrate ion; NO\(_3\)-: nitrite ion; MPO is a major source of ROS in the CNS; NADPH oxidase is a very important pro-oxidase that causes oxidative stress; MnSOD: manganese superoxide dismutase; iNOS: inducible nitric oxide synthase, and inflammatory cytokines (i.e., IL-1β and tumor necrosis factor-α) (Ekdahl et al., 2003; Monje et al., 2003; Brovkovych et al., 2008; Cacci et al., 2008). These factors might cause indirect damage to neurons and astrocytes after stroke.

ROS avidly interact with large numbers of molecules, including other small inorganic molecules, as well as proteins, lipids, carbohydrates, and nucleic acids. Through such interactions, ROS may irreversibly destroy or alter the function of the target molecules. Consequently, ROS have been increasingly identified as major contributors to damage in biological organisms (Bedard and Krause, 2007; Diwanji and Bergmann, 2020). Related research has shown that ROS production increases BBB permeability and monocyte migration, and ROS activated MMP1, MMP2, and MMP9 (Haorah et al., 2007). The protein tyrosine kinase (PTK)-dependent pathway reduces the activity of tissue inhibitor of metalloproteinase 12, and increased MMP activity is closely related to the degradation of tight junctions in BMVEC proteins (Song et al., 2018). MMPs, PTKs, and antioxidant inhibitors can prevent monocyte migration, suggesting that oxidative stress causes BBB damage through the activation of MMPs and the PTK-mediated degradation of BMVEC proteins (Haorah et al., 2007). NADPH and inducible NO synthase produce superoxide, peroxynitrite, and oxidize endothelial NO synthase dimer in endothelial cells (Xu et al., 2006). Together, these compounds increase the damage to the central nervous system.

Figure 1 | Response caused by myeloperoxidase (MPO) in blood vessels before stroke.

MPO may promote stroke due to damage to the arterial wall through direct oxidation and indirect effects on blood vessel integrity and function, driving a core rich in low-density lipoprotein and promoting the formation of atherosclerotic plaques by foamy macrophages. These plaques affect the function, distribution, and flow of serum cholesterol due to lipid peroxidation. The activation of matrix metalloproteinases leads to atherosclerotic plaque rupture and instability, which can stimulate local occlusive thrombosis through P-selectin interactions. Depleting nitric oxide (NO) can impair vasodilation resistance against inflammation and impair vascular reactivity.
tissue susceptibility to ischemic injury and triggers various molecular cascades, resulting in increased BBB permeability, brain edema, bleeding, inflammation, and neuronal death. Furthermore, free radicals can activate MMPs, which is a critical step in damaging the BBB (Figure 2).

The inflammatory response and oxidative stress both damage the BBB and disrupt neurogenesis. Disorders of learning, language memory, and execution ability are most likely to occur after a stroke, primarily due to damage in corresponding brain areas, such as the cerebral cortex and hippocampus. Functional damage to these brain areas occurs due to repeated ischemia and inflammatory infiltration, which gradually reduces the recruitment of stem cells, affecting neurogenesis (Lin et al., 2018; Deng et al., 2021).

### Potential of Myeloperoxidase in Stroke

The genetic risk and predictive value of MPO in stroke

The genetic contributions of MPO levels to ischemic stroke and related to the cavity subtype (odds ratio 1.05, \( P = 0.022 \)). These results suggest that increased genetic variations in MPO levels increase the risk of primary intracerebral hemorrhage and lacunar stroke, proving that MPO is correlated with the risk of small vessel disease. High expression of the MPO gene can increase the risk of stroke. Simultaneously, MPO plays an important inflammatory role. The effects of a lack or low expression of the MPO gene were examined by Manso et al. (2011), who indicated that the lack of MPO does not significantly impact human life. Although MPO is an important molecule produced by neutrophils and is involved in the killing of certain microorganisms, no data or research has shown that a lack of MPO results in increased susceptibility to severe or persistent infections. Although serious infections occasionally occur in patients with MPO deficiency, these affect fewer than 5% of patients with MPO deficiency, indicating a low incidence (Kitahara et al., 1981). Visceral candida infections have been reported in patients with MPO deficiency; however, Stendahl et al. (1984) have shown that the microbical and fungicidal activities of MPO-deficient neutrophils are only slightly weakened compared with normal neutrophils. Some studies have shown that MPO-deficient neutrophils have prolonged respiratory bursts, resulting in increased H2O2 production in response to stimulation. These factors may compensate for the lack of peroxidase (Cramer et al., 1982). Therefore, on the basis of research performed in MPO knockout models, further relevant research can be performed to observe only that the MPO-specific inhibitor AM1, in response to the loss of MPO production, to determine whether the MPO blockade will cause serious damage to the body. Such research should also seek to observe changes in the physiological regulation mechanisms mediated by MPO. If MPO knockout or knockdown shows little effect on the body, MPO inhibition could be applied to animal models of stroke to determine the therapeutic effects of MPO inhibition.

MPO as a therapeutic target in stroke

Malle et al. (2007) found that MPO can be used as a target for future drug development. Related drugs inhibit MPO activity and inhibit substrate production by combining halide binding sites with an aromatic substrate or inhibitor binding sites. They included 4-aminobenzoic acid amide, N-phenylacetamide, and melatonin (Malle et al., 2007).

On the basis of the hypothesis that MPO targets can be used as drugs, many animal experiments have been performed to examine the application of MPO inhibitors to stroke models in recent years. The classic MPO-specific inhibitor, 4-aminobenzoic acid amide, is a common drug used in stroke treatment research, and neurogenesis following ischemic stroke increased after 4-aminobenzoic acid amide treatment. The inhibition of MPO also increased the levels of brain-derived neurotrophic factor, phosphorylated C-receptor, acetyl h3 receptor, Cys-X-Cys receptor 4, and neuronal core antigen and reduced inflammatory cell infiltration mediated by MMP9. These results underscore the detrimental role of MPO activity in post-ischemia neurogenesis. A series of experiments demonstrated that MPO activity is inversely proportional to neurogenesis after stroke, and the inhibition of MPO activity increases cell proliferation and improves neurogenesis after ischemic stroke (Dreixelus et al., 2019; Kim et al., 2019; Qiu et al., 2021). They further found that the protective environment induced by MPO inhibition or the knockout of MPO genes can reduce inflammatory cell aggregation and increase survival factors, which can improve stroke outcomes. MPO inhibition may represent a promising therapeutic target for stroke therapy, possibly even days after the stroke has occurred (Kim et al., 2016).

New MPO inhibitors are being discovered continuously. For example, N-acetyl lysyl-tyrosyl cysteine amide can inhibit the activity of MPO, which can reduce the numbers of M1 microglia and N1 neutrophils in the brains of mouse models, protecting neuronal function (Yu et al., 2018). Many drugs can also exert antioxidant and anti-inflammatory effects and inhibit MPO. For example, in the study of ischemic stroke, after using rosmarinic acid (Fontes et al., 2016), melatonin (Pei and Cheung, 2004), tropisetron (Daneshmand et al., 2011), and the traditional Chinese medicine extract Leonurus heterophyllus (Liang et al., 2011), a significant decrease in the amount and activity of MPO was observed. Importantly, cerebral infarction and neuronal damage were improved. Another example is in the study of hemorrhagic stroke. Lee et al. (2006) induced cerebral hemorrhage by injecting collagenase into the rat basal ganglia and administered memantine to inhibit inflammation. They found that the number of MPO-positive cells around the hematoma was significantly reduced in the memantine-treated group, which induced functional recovery after cerebral hemorrhage (Lee et al., 2006).

Although no MPO inhibitors are currently approved for use in clinical stroke patients, many preclinical candidate drugs are under development, and one candidate drug has completed Phase IIa clinical trials (Churg et al., 2012; Forbes et al., 2013; Ward et al., 2013). On the basis of the above review, MPO plays a vital role in stroke occurrence and development. After MPO inhibition, neurogenesis becomes active, and stroke recovery improves; therefore, MPO is expected to become a new target for stroke treatment.

### Conclusions

MPO leads to a significant increase in stroke occurrence and development. The overexpression of MPO typically results in impaired BBB permeability. For patients with congenital or acquired loss of MPO expression, the effects on their immunity are not significant. Therefore, MPO can be targeted clinically for stroke treatment and potentially other inflammation-related diseases. Currently, no MPO inhibitors have been approved for clinical use, and the most commonly used specific inhibitor of MPO, ABAH, has a strong toxic effect on the human body. Moreover, including those mentioned in our article, are not specific inhibitors, and few studies have been performed on these inhibitors, none of which have reached the level of clinical trial. Whether these nonspecific inhibitors have side effects on the human body remains unclear. The specific damage mechanism of MPO also remains unclear, and more research is necessary to understand the underlying mechanisms. The specific etiological mechanism that leads to the activation of MPO during the occurrence and development of stroke also requires further clarification. Neutrophils are a key source of MPO production, and central immune cells can also produce MPO. Additional MPO-targeting drugs that are safe for clinical use must be developed.
References

Agner K (1941) Veroperoxidase: a ferrous isolated from leukocytes. Acta Physiol Scand 1:2-12.

Al Mamun A, Chaushan A, Yu H, Xu Y, Sharmeen L, Liu F (2018) Interferon regulatory factor 4/S signaling impacts on microglial activation after ischemic stroke in mice. Eur J Neurosci 50:482-491.

Ancili M, Pauliani I, Pellettere C (2005) Nitric oxide modulates peristaltic muscle activity associated with fluid circulation in the soya pea Renilla kinetik. J Exp Biol 208:2005-2017.

Avan A, Digaleh H, Di Napoli M, Stranges S, Behrouz R, Shojaeianbabaei G, Amiri A, YWP, YNZ. All authors read and approved the final manuscript.

Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245-313.

Bennett H, Kegelnig N, Prisch J, Gottschall B, Goerster M, Deppe MR, Reicher H, Nusshold C, Plastina I, Hammer G, Faull LR, Manger WG, Manger NE (2011) Neuroinflammation in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons AttributionNonCommercial-ShareAlike 4.0 license, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

©Author(s) (unless otherwise stated in the text of the article) 2022. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Reviewer: Rayudu Gopalakrishna, University of Southern California, USA.

Ekdahl CT, Claassen JH, Bonde S, Kokaia Z, Lindvall O (2003) Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 100:13632-13637.

El Border D, Joliet L, Pan W, Filipe JG (2008) Myeloperoxidase delays neutrophil apoptosis through C101b2/C101b interaction and proline inflagrants. J Biol Chem 283:13705-13712.

Facci L, Bharat A, Muzzo S, Skaper SD, Giusti P (2018) Serum amyloid A primes microglia for ATP-dependent interleukin-1β release. J Neuroinflammation 15:164.

Feng W, Wang Y, Liu QZ, Zhang X, Han R, Miao YZ, Qin ZH (2017) Microglia activation contributes to quinolinic acid-induced neuronal excitotoxicity through Tnf-a.

Fontaine EA, de Souza CM, de Souza Neves JC, Menezes AP, Santos do Carro MR, Fernandes FD, de Araujo PR, de Andrade GM (2016) Rosmarinic acid prevents against memory deficits in ischemic animals. Behav Brain Res 297:91-103.

Forbes LV, Sögren T, Auwärter F, Jenkins DW, Thong B, Laughton D, Hemmes P, Paeraudeau G, Turner R, Eriksson H, Unitt JF, Kettlsruhe AE (2013) Potent reversible inhibition of myeloperoxidase by hydroxamic acids. J Biol Chem 288:36636-36647.

Fu X, Kassim SV, Pars W, Haq A, Rottini GD, Bramezza M, Cirielli S, Patriarca P (2017) Structure of human promyeloperoxidase (proMPO) and the role of the cysteine switch domain of pro-matriptase (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 292:41779-41787.

Georgieva MG (2020) Risk Factors for ischemic stroke in younger adults: a focused update. Stroke 51:729-735.

Gorudjo IV, Mikhailikh EV, Sokolov AV, Gregoriou DV, Kostevych VA, Vasilen BV, Cherenkov SV, Sanasenko OM (2017) The production of reactive oxygen and halogen species by neutrophils in response to monomeric forms of myeloperoxidase. Biophys 62:919-925.

Gray B, Robertson CM, Diakouka BS, Bautista J, Mascarenhas F, Robertson CM, Diacovo MJ, Montgrain V, Lam PM, van den Bogaert B, van den Berg W, van den Berg W, van der Velden C, Ansari H, et al. (2011) Global, regional, and national age-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1736-1788.

Gelfand S, Sunnemend D, Eriksson H, Olson L, Gartner D (2017) Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease. Cell Res 36:445-449.

George MG (2020) Risk Factors for ischemic stroke in younger adults: a focused update. Stroke 51:729-735.

Gorudjo IV, Mikhailikh EV, Sokolov AV, Gregoriou DV, Kostevych VA, Vasilen BV, Cherenkov SV, Sanasenko OM (2017) The production of reactive oxygen and halogen species by neutrophils in response to monomeric forms of myeloperoxidase. Biophys 62:919-925.

Gray E, Thomas TL, Betmouni S, Scolding N, Love S (2008) Elevated activity and microglial polarization in mice model of rheumatoid arthritis. Sci Rep 9:2173.

Grishkowska I, Paumann-Page M, Tscheliessnig R, Stampler J, Hofbauer S, Soudi M, Thomas TL, Betmouni S, Scolding N, Love S (2008) Elevated activity and microglial polarization in mice model of rheumatoid arthritis. Sci Rep 9:2173.

Huang M, Bergmann CC (2000) Neuronal ablation of alpha/beta interferon (IFN-α/β) signaling exacerbates central nervous system viral dissemination and impairs IFN-γ responsiveness in microglia/macrophages. J Virol 74:189-197.

Iancu A, Sirbu E (2020) Linking myeloperoxidase with subclinical atherosclerosis in adults with metabolic syndrome. Wien Klin Wochenschr 132:150-154.

Ibañez A, Amoros A, Garcia A, Mirón A, Heras FJ, Roldan MA, Atkin CL, Hasstedt SJ (1981) Hereditary myeloperoxidase deficiency. J Clin Invest 67:75-82.

Ike Ekdahl CT, Claassen JH, Bonde S, Kokaia Z, Lindvall O (2003) Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci U S A 100:13632-13637.

El Border D, Joliet L, Pan W, Filipe JG (2008) Myeloperoxidase delays neutrophil apoptosis through C101b2/C101b interaction and proline inflagrants. J Biol Chem 283:13705-13712.

Facci L, Bharat A, Muzzo S, Skaper SD, Giusti P (2018) Serum amyloid A primes microglia for ATP-dependent interleukin-1β release. J Neuroinflammation 15:164.

Feng W, Wang Y, Liu QZ, Zhang X, Han R, Miao YZ, Qin ZH (2017) Microglia activation contributes to quinolinic acid-induced neuronal excitotoxicity through Tnf-a. Ann Neurol 82:696-709.

Fontaine EA, de Souza CM, de Souza Neves JC, Menezes AP, Santos do Carro MR, Fernandes FD, de Araujo PR, de Andrade GM (2016) Rosmarinic acid prevents against memory deficits in ischemic animals. Behav Brain Res 297:91-103.

Forbes LV, Sögren T, Auwärter F, Jenkins DW, Thong B, Laughton D, Hemmes P, Paeraudeau G, Turner R, Eriksson H, Unitt JF, Kettlsruhe AE (2013) Potent reversible inhibition of myeloperoxidase by hydroxamic acids. J Biol Chem 288:36636-36647.

Fu X, Kassim SV, Pars W, Haq A, Rottini GD, Bramezza M, Cirielli S, Patriarca P (2017) Structure of human promyeloperoxidase (proMPO) and the role of the cysteine switch domain of pro-matriptase (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 292:41779-41787.

Feng W, Wang Y, Liu QZ, Zhang X, Han R, Miao YZ, Qin ZH (2017) Microglia activation contributes to quinolinic acid-induced neuronal excitotoxicity through Tnf-a. Ann Neurol 82:696-709.
